Eliminating contamination risks and creating safer medicines with animal origin free (AOF) proteins.
Currently Operating in 30 Regions
July 29, 2021
The earnings before interest, tax, depreciation and ammortisation (EBITDA) margins expanded 210 basis points YoY to 31.3 percent; however, on sequential basis (QoQ), Laurus' EBITDA margins were...Read on Moneycontrol »
November 29, 2020
Motilal Oswal Securities maintains 'buy' rating on Laurus Labs with target price of Rs 410 per shareRead on bsindia »
November 25, 2020
Laurus Labs announced it has signed a definitive agreement to acquire 72.55% of Richcore’s shares from Eight Roads Ventures and VenturEast. This acquisition marks Laurus Labs’ entry into the...Read on hrnxt.com »
July 21, 2020
Biotech company Richcore LifeSciences launches second recombinant protein manufacturing facility in Tumkur
Richore LifeSciences claims that the new facility will include 180 thousand Litre fermentation capability to produce multiple recombinant biotech productsRead on YourStory.com »
More Ventures in Health
Get the Unreasonable Newsletter
Get twice-monthly updates on Laurus Bio (formerly Richcore India) and over 370 other ventures working to solve the world's toughest problems.